[The effect of thalidomine-induced NF-kappa B activation on malignant transformation of hepatocytes].
Yao
Deng-fu
DF
Research Center of Clinical Medicine, Affiliated Hospital, Nantong University, Nantong 226001, China. yaodf@ahnmc.com
Yu
Hong-bo
HB
Shen
Jun-jun
JJ
Wang
Yi-lang
YL
Wu
Xin-hua
XH
Qiu
Li-wei
LW
Wu
Wei
W
D015073:2-Acetylaminofluorene; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology*; D007150:Immunohistochemistry; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology*; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013792:Thalidomide / Q000494:pharmacology*
D020533:Angiogenesis Inhibitors; D016328:NF-kappa B; D013792:Thalidomide; D015073:2-Acetylaminofluorene